Shots:
- The P-IIIb PONENTE study evaluates the safety & efficacy of Fasenra (30mg, SC, q8w) in adult patients with sev. eosinophilic asthma on high-dose ICS + LABA & long-term use of OCS therapy with/out additional asthma controlled
- Results: 97% of patients maintained a low OCS dose of ≤5mg across blood eosinophil counts @6mos., 3% of patients completed reduction phase to increase maintenance OCS dosage, exacerbation free (85%) compared to baseline (16%) @12mos., improvement (18%) or no change (39%) in asthma control from the end of OCS-reduction to a maintenance phase
- Fasenra is currently approved as an add-on maintenance treatment for asthma & is approved for self-administration in the US, EU & other countries
Click here to read full press release/ article | Ref: AstraZeneca | Image: Reuters
The post AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021 first appeared on PharmaShots.
